Literature DB >> 19461820

The influence of prescription monitoring programs on chronic pain management.

Jing Wang1, Paul J Christo.   

Abstract

BACKGROUND: Abuse of prescribed controlled substance has become a serious social as well as health care issue over the past decade. A particularly alarming trend exists among patients aged 12 to 17. Common abuse behaviors include doctor shopping, drug theft, feigned pain symptoms to gain health care access, drug sharing, prescription forgery, and improper prescription practices. In response to this epidemic of abuse, many states have adopted prescription monitoring programs (PMPs). Such programs first originated in the early twentieth century. As of 2006, 38 states had such programs, many of which are supported by federal grants. As PMPs become more widespread, they have also increased in sophistication. By keeping a record of the prescription and dispensing of narcotics, these programs are able to build a comprehensive data network for tracking prescription medications. These databases aid law enforcement agencies in investigations of narcotic trafficking; they also help state regulatory boards to monitor improper prescription practices.
OBJECTIVE: This manuscript examines the basic structure of a PMP, including the way the data are collected and the way these data are stored and used. It also looks at the organizational differences amongst state programs. NASPER and Harold Rogers are two federal programs that provide funding to the state PMPs, and the current study examines the differences as well as similarities between these 2 programs. This study also compares the results of 2 reports: the U.S. General Accounting Office Study and the Twillman study.& Both studies have evaluated the efficiency of the PMPs. DISCUSSION: The U.S. General Accounting Office Study showed that while considerable differences exist among the state PMPs, these programs not only reduce the time and effort for law enforcement agencies to conduct investigations, but also cut the supply of prescription medications. However, the Twillman report suggests that prescription programs caused a shift in prescription practice, while the actual rate of abuse may not have been reduced. These 2 studies both point to the challenges the PMPs face. However, more recent data suggest that proactive use of the PMPs results in the decreased growth of prescription medication sales. Finally, a number of states have also begun to objectively evaluate the efficiencies of the system.
CONCLUSION: Many states have developed PMPs to help regulatory agencies as well as physicians detect prescription drug abuse. Limited data so far suggest that such programs reduce abuse practices. In addition, proactive usage of the data further prevents abuse.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19461820

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  28 in total

1.  The effects of North Carolina's prescription drug monitoring program on the prescribing behaviors of the state's providers.

Authors:  Chris Ringwalt; Mariana Garrettson; Apostolos Alexandridis
Journal:  J Prim Prev       Date:  2015-04

Review 2.  Opioid Prescribing in an Opioid Crisis: What Basic Skills Should an Oncologist Have Regarding Opioid Therapy?

Authors:  Joseph Arthur; Akhila Reddy
Journal:  Curr Treat Options Oncol       Date:  2019-04-01

3.  The Case for a PDMP in Missouri.

Authors:  Sam L Page
Journal:  Mo Med       Date:  2017 Jul-Aug

Review 4.  Windmills and pill mills: can PDMPs tilt the prescription drug epidemic?

Authors:  Hallam Gugelmann; Jeanmarie Perrone; Lewis Nelson
Journal:  J Med Toxicol       Date:  2012-12

Review 5.  Strategies to prevent opioid misuse, abuse, and diversion that may also reduce the associated costs.

Authors:  Kathryn L Hahn
Journal:  Am Health Drug Benefits       Date:  2011-03

6.  Identification of barriers to safe opioid prescribing in primary care: a qualitative analysis of field notes collected through academic detailing.

Authors:  Christopher D Saffore; Sarette T Tilton; Stephanie Y Crawford; Michael A Fischer; Todd A Lee; A Simon Pickard; Lisa K Sharp
Journal:  Br J Gen Pract       Date:  2020-07-30       Impact factor: 5.386

7.  Evolution and convergence of state laws governing controlled substance prescription monitoring programs, 1998-2011.

Authors:  Corey S Davis; Matthew Pierce; Nabarun Dasgupta
Journal:  Am J Public Health       Date:  2014-06-12       Impact factor: 9.308

8.  A Multicomponent Intervention to Improve Primary Care Provider Adherence to Chronic Opioid Therapy Guidelines and Reduce Opioid Misuse: A Cluster Randomized Controlled Trial Protocol.

Authors:  Karen E Lasser; Christopher Shanahan; Victoria Parker; Donna Beers; Ziming Xuan; Orlaith Heymann; Allison Lange; Jane M Liebschutz
Journal:  J Subst Abuse Treat       Date:  2015-07-15

Review 9.  Buprenorphine Prescribing: To Expand or Not to Expand.

Authors:  Xiaofan Li; Daryl Shorter; Thomas R Kosten
Journal:  J Psychiatr Pract       Date:  2016-05       Impact factor: 1.325

10.  The latent structure and predictors of non-medical prescription drug use and prescription drug use disorders: a national study.

Authors:  Carlos Blanco; Claudia Rafful; Melanie M Wall; Chelsea J Jin; Bradley Kerridge; Robert P Schwartz
Journal:  Drug Alcohol Depend       Date:  2013-08-17       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.